Sarepta Therapeutics/SRPT

$118.31

-3.71%
-
1D1W1MYTD1YMAX

About Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Ticker

SRPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Douglas Ingram

Employees

1,314

Headquarters

Cambridge, United States

SRPT Metrics

BasicAdvanced
$11.53B
Market cap
-
P/E ratio
-$6.15
EPS
0.96
Beta
-
Dividend rate
$11.53B
0.9555
$159.89
$55.25
884.54K
3.946
3.452
131.789
144.064
-16.77%
-86.15%
-20.94%
9.275
13.402
13.899
33.26%
23.45%
32.04%

What the Analysts think about SRPT

Analyst Ratings

Majority rating from 23 analysts.
Buy

Price Targets

Average projection from 19 analysts.
40.26% upside
High $224.00
Low $128.00
$118.31
Current price
$165.94
Average price target

SRPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
11.49% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$396.7M
19.56%
Net income
$45.6M
-211.49%
Profit margin
11.49%
-193.26%

SRPT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3,083.2%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$5.86
-$0.27
-$0.46
$0.47
-
Expected
-$1.38
-$1.78
-$1.23
$0.01
-$0.07
Surprise
323.65%
-84.81%
-62.62%
3,083.2%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Sarepta Therapeutics stock?

Sarepta Therapeutics (SRPT) has a market cap of $11.53B as of April 16, 2024.

What is the P/E ratio for Sarepta Therapeutics stock?

The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 0 as of April 16, 2024.

Does Sarepta Therapeutics stock pay dividends?

No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Sarepta Therapeutics dividend payment date?

Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.

What is the beta indicator for Sarepta Therapeutics?

Sarepta Therapeutics (SRPT) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Sarepta Therapeutics stock price target?

The target price for Sarepta Therapeutics (SRPT) stock is $165.94, which is 40.26% above the current price of $118.31. This is an average based on projections from 19 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Sarepta Therapeutics stock

Buy or sell Sarepta Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing